{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:40:40Z","timestamp":1793191240308,"version":"4.5.0"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T00:00:00Z","timestamp":1094169600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathology International"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p>Rituximab is widely used for the treatment of B\u2010cell non\u2010Hodgkin's lymphoma (NHL), and encouraging results have been obtained. However, some CD20\u2010positive NHL show minimal response to rituximab, indicating that the treatment effect depends on the presence or absence of an unidentified factor. We analyzed the relationship between the effect of rituximab plus chemotherapy and expression of Ki\u201067, p53 and bcl\u20102 and several clinical variables in cases of B\u2010NHL, particularly follicular lymphoma (FL) and diffuse large B\u2010cell lymphoma (DLBCL). Forty\u2010four patients were included in the present study, and the overall treatment response rate was 68%. Twelve of 30 patients (40%) achieved a complete response, five (16%) reached an unconfirmed complete response and 13 (43%) achieved a partial response. A high serum lactate dehydrogenase level and International Prognostic Index of high or high intermediate risk were associated with a decreased response in the case of FL. Immunohistochemical assays were performed in 18 FL patients (55%) and 15 DLBCL patients (45%). Significant correlation was found between an inferior response to treatment and high Ki\u201067 expression in the cases of FL (<jats:italic>P<\/jats:italic>\u2003=\u20030.006). p53 and bcl\u20102 expression did not correlate significantly with the response rate. The cell cycle appears to be an important factor in the efficacy of rituximab treatment. Ki\u201067 expression might be a predictor of efficacy of rituximab plus chemotherapy.<\/jats:p>","DOI":"10.1111\/j.1440-1827.2004.01678.x","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T08:57:35Z","timestamp":1094201855000},"page":"667-674","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki\u201067 expression"],"prefix":"10.1111","volume":"54","author":[{"given":"Bungo","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiko","family":"Yamochi\u2010Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tomoyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Omine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell\u2010associated antigen on leukemia and lymphoma: a model of human B cell differentiation","volume":"63","author":"Anderson KC","year":"1984","journal-title":"Blood"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte\u2010specific antigen","volume":"124","author":"Sashenko P","year":"1980","journal-title":"J Immunol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_8_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01692.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3442"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1343"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:15"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00421"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.1999.00980.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830160802"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3900"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation","volume":"135","author":"Tedder TF","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.4049\/jimmunol.135.6.3795","article-title":"The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle","volume":"135","author":"Golay JT","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoid and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose AL","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of the cell proliferation\u2010associated human nuclear antigen defined by the monoclonal antibody Ki\u201067","volume":"133","author":"Gerdes J","year":"1984","journal-title":"J Immunol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2184.1996.d01-2.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418699432040"},{"key":"e_1_2_6_30_2","first-page":"487","article-title":"MIB1 (Ki\u201067) expression in non\u2010Hodgkin's lymphomas","volume":"17","author":"Kalogeraki A","year":"1997","journal-title":"Anticancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.2.601"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1038"},{"key":"e_1_2_6_34_2","first-page":"755","article-title":"Correlations between apoptosis and proliferative indices in malignant non\u2010Hodgkin's lymphomas","volume":"142","author":"Leoncini L","year":"1993","journal-title":"Am J Pathol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.4.879.879"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.265.265"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1046.1046"},{"key":"e_1_2_6_38_2","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down\u2010regulation of bcl\u20102 and sensitization of B\u2010cell non\u2010Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas S","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_39_2","first-page":"836","article-title":"Rituximab modifies the cisplatin\u2010mitochondrial signaling pathway, resulting in apoptosis in cisplatin\u2010resistant non\u2010Hodgkin's lymphoma","volume":"8","author":"Alas S","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.10.2701.bloodjournal79102701"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Coco FL","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370804"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.61"},{"key":"e_1_2_6_44_2","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B\u2010cell non\u2010Hodgkin's lymphoma","volume":"90","author":"Koduru PRK","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000163"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.389"}],"container-title":["Pathology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1827.2004.01678.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1827.2004.01678.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:23:29Z","timestamp":1696875809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1827.2004.01678.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1440-1827.2004.01678.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1827.2004.01678.x","archive":["Portico"],"relation":{},"ISSN":["1320-5463","1440-1827"],"issn-type":[{"value":"1320-5463","type":"print"},{"value":"1440-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}